JP2017524652A - 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 - Google Patents

一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 Download PDF

Info

Publication number
JP2017524652A
JP2017524652A JP2016568591A JP2016568591A JP2017524652A JP 2017524652 A JP2017524652 A JP 2017524652A JP 2016568591 A JP2016568591 A JP 2016568591A JP 2016568591 A JP2016568591 A JP 2016568591A JP 2017524652 A JP2017524652 A JP 2017524652A
Authority
JP
Japan
Prior art keywords
use according
dose
formula
therapy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016568591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524652A5 (cg-RX-API-DMAC7.html
Inventor
アイ−ミン フイ，
アイ−ミン フイ，
リチャード ラボツカ，
リチャード ラボツカ，
ニーラジ グプタ，
ニーラジ グプタ，
カーシク ベンカタクリシュナン，
カーシク ベンカタクリシュナン，
グオフイ ルイ，
グオフイ ルイ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of JP2017524652A publication Critical patent/JP2017524652A/ja
Publication of JP2017524652A5 publication Critical patent/JP2017524652A5/ja
Priority to JP2019104381A priority Critical patent/JP6906564B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016568591A 2014-05-20 2015-05-19 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤 Pending JP2017524652A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019104381A JP6906564B2 (ja) 2014-05-20 2019-06-04 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462000991P 2014-05-20 2014-05-20
US62/000,991 2014-05-20
US201462019600P 2014-07-01 2014-07-01
US62/019,600 2014-07-01
US201462088154P 2014-12-05 2014-12-05
US62/088,154 2014-12-05
PCT/US2015/031633 WO2015179443A1 (en) 2014-05-20 2015-05-19 Boron-containing proteasome inhibitors for use after primary cancer therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019104381A Division JP6906564B2 (ja) 2014-05-20 2019-06-04 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤

Publications (2)

Publication Number Publication Date
JP2017524652A true JP2017524652A (ja) 2017-08-31
JP2017524652A5 JP2017524652A5 (cg-RX-API-DMAC7.html) 2018-06-28

Family

ID=54554652

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016568591A Pending JP2017524652A (ja) 2014-05-20 2015-05-19 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤
JP2019104381A Active JP6906564B2 (ja) 2014-05-20 2019-06-04 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019104381A Active JP6906564B2 (ja) 2014-05-20 2019-06-04 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤

Country Status (21)

Country Link
US (5) US20150335668A1 (cg-RX-API-DMAC7.html)
EP (1) EP3145526A1 (cg-RX-API-DMAC7.html)
JP (2) JP2017524652A (cg-RX-API-DMAC7.html)
KR (2) KR102481856B1 (cg-RX-API-DMAC7.html)
CN (1) CN106659761A (cg-RX-API-DMAC7.html)
AU (2) AU2015264272A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016026774A8 (cg-RX-API-DMAC7.html)
CA (1) CA2949517A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016002948A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160577A (cg-RX-API-DMAC7.html)
EA (1) EA201692332A1 (cg-RX-API-DMAC7.html)
IL (2) IL249025B (cg-RX-API-DMAC7.html)
MA (1) MA39964A (cg-RX-API-DMAC7.html)
MX (2) MX2016015267A (cg-RX-API-DMAC7.html)
PH (1) PH12016502301A1 (cg-RX-API-DMAC7.html)
SG (2) SG10202003693RA (cg-RX-API-DMAC7.html)
TN (1) TN2016000492A1 (cg-RX-API-DMAC7.html)
TW (1) TWI746422B (cg-RX-API-DMAC7.html)
UA (1) UA121389C2 (cg-RX-API-DMAC7.html)
UY (1) UY36132A (cg-RX-API-DMAC7.html)
WO (1) WO2015179443A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079572A1 (en) * 2015-11-04 2017-05-11 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having multiple myeloma
EP3493793A4 (en) * 2016-08-04 2020-04-01 Millennium Pharmaceuticals, Inc. COMBINATION OF PROTEASOME INHIBITORS AND ANTI-CD30 ANTIBODIES
WO2018123925A1 (ja) * 2016-12-28 2018-07-05 第一三共株式会社 アルポート症候群治療薬
WO2019020099A1 (zh) 2017-07-28 2019-01-31 成都地奥九泓制药厂 一种硼酸酯化合物、其合成方法及其用途
US20250059214A1 (en) * 2021-12-06 2025-02-20 Pretzel Therapeutics, Inc. Amide-containing lonp1 inhibitor compounds, uses and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524903A (ja) * 2008-06-17 2011-09-08 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ボロン酸エステル化合物およびその医薬組成物

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2160413A (en) 1935-04-16 1939-05-30 Schering Ag Polyiodo derivatives of acylamino acids and their salts and a method of making the same
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
JPS6233170A (ja) 1985-08-07 1987-02-13 Tokuyama Soda Co Ltd 環状ポリエ−テル化合物
JPH0813759B2 (ja) 1986-09-01 1996-02-14 富士写真フイルム株式会社 アルコキシベンゼン誘導体の製造方法
JP2512303B2 (ja) 1987-03-20 1996-07-03 呉羽化学工業株式会社 ２−オキサゾリン−４，５−ジオンのフエニルヒドラゾン誘導体
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
MX9206628A (es) 1991-11-22 1993-05-01 Boehringer Ingelheim Pharma Ester de prolinaboronato y metodo para su preparacion.
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
EP0583536B1 (en) 1992-08-14 1997-03-05 The Procter & Gamble Company Liquid detergents containing an alpha-amino boronic acid
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US5935944A (en) 1993-09-10 1999-08-10 Neutron Technology Corporation Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5834487A (en) 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
WO1998035691A1 (en) 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
WO1999015183A1 (en) 1997-09-25 1999-04-01 Proscript Inc. PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES
JP2002508321A (ja) 1997-12-16 2002-03-19 セフアロン・インコーポレーテツド 抗腫瘍薬としての使用のための多触媒性プロテアーゼ阻害剤
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
WO2000024392A1 (en) 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
CA2376965A1 (en) 1999-07-07 2001-01-11 Timothy Patrick Forsyth Peptide boronic acid inhibitors of hepatitis c virus protease
SE0100714D0 (sv) 2000-07-13 2001-02-28 Ap Biotech Ab Reaction vessel and method for distributing fluid in such a vessel
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
JP2002145848A (ja) 2000-11-10 2002-05-22 Kyorin Pharmaceut Co Ltd アルケニルアミノ酸誘導体及びその製造法
EP2251344B2 (en) 2001-01-25 2024-04-24 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Formulation of boronic acid compounds
CN100415770C (zh) 2001-05-30 2008-09-03 诺瓦提斯公司 2－{[n－(2－氨基－3－(杂芳基或芳基)丙酰基)－氨基酰基]－氨基}－烷基硼酸衍生物
JPWO2003033506A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
WO2003033507A1 (en) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same
AU2003219652A1 (en) 2002-01-08 2003-07-30 Eisai Co. Ltd. Eponemycin and epoxomicin analogs and uses thereof
WO2003105860A1 (en) 2002-06-14 2003-12-24 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
GB0405267D0 (en) 2004-03-09 2004-04-21 Trigen Ltd Compounds
DK1756121T3 (da) 2004-03-30 2012-01-09 Millennium Pharm Inc Syntese af borester- og borsyreforbindelser
US8088741B2 (en) 2004-05-10 2012-01-03 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AU2006242446A1 (en) 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
WO2007005991A1 (en) 2005-07-05 2007-01-11 Trustees Of Tufts College Inhibitors of fibroblast activation protein alpha
US20090304631A1 (en) 2006-01-27 2009-12-10 David Alan Campbell Hepatitis c serine protease inhibitors and uses therefor
CL2007002499A1 (es) 2006-08-30 2008-03-14 Phenomix Corp Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
NZ582693A (en) 2007-08-06 2012-01-12 Millennium Pharm Inc Boron-containing proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EA029521B1 (ru) 2010-03-31 2018-04-30 Милленниум Фармасьютикалз, Инк. Производные 1-амино-2-циклопропилэтилбороновой кислоты

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524903A (ja) * 2008-06-17 2011-09-08 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ボロン酸エステル化合物およびその医薬組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIAMPAOLO MERLINI: "MLN9708, A NOVEL, INVESTIGATIONAL ORAL PROTEASOME INHIBITOR, IN PATIENTS WITH RELAPSED OR 以下備考", 54TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY (ASH), JPN5017005815, December 2012 (2012-12-01), US, ISSN: 0004067625 *
SHAJI K KUMAR: "WEEKLY MLN9708, AN INVESTIGATIONAL ORAL PROTEASOME INHIBITOR, IN RELAPSED/REFRACTORY 以下備考", ASCO ANNUAL MEETING 2013, JPN5017005814, June 2013 (2013-06-01), ISSN: 0004067624 *
村上 博和 HIROKAZU MURAKAMI: "多発性骨髄腫の治療指針 Diagnosis and management guideline of multiple myeloma", 日本臨牀 ＶＯＬ．６５（１２） THE JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 65, no. 12, JPN6019010794, 2007, pages 2167 - 2176, ISSN: 0004067626 *

Also Published As

Publication number Publication date
EA201692332A1 (ru) 2017-04-28
AU2021200370B2 (en) 2022-11-03
UY36132A (es) 2015-11-30
US20210177871A1 (en) 2021-06-17
AU2021200370A1 (en) 2021-03-18
US20190343851A1 (en) 2019-11-14
KR102481856B1 (ko) 2022-12-26
CL2016002948A1 (es) 2017-03-31
MA39964A (fr) 2015-11-26
KR20170005042A (ko) 2017-01-11
CA2949517A1 (en) 2015-11-26
MX2021009044A (es) 2021-09-21
KR20220097553A (ko) 2022-07-07
MX2016015267A (es) 2017-02-22
BR112016026774A2 (pt) 2017-08-15
TWI746422B (zh) 2021-11-21
JP6906564B2 (ja) 2021-07-21
US20200171061A1 (en) 2020-06-04
JP2019147837A (ja) 2019-09-05
WO2015179443A1 (en) 2015-11-26
SG11201609259VA (en) 2016-12-29
IL249025B (en) 2020-05-31
IL274042A (en) 2020-06-30
EP3145526A1 (en) 2017-03-29
US20190125773A1 (en) 2019-05-02
IL249025A0 (en) 2017-01-31
NZ725948A (en) 2024-01-26
TN2016000492A1 (en) 2018-04-04
PH12016502301A1 (en) 2017-02-13
CN106659761A (zh) 2017-05-10
BR112016026774A8 (pt) 2021-07-13
AU2015264272A1 (en) 2016-11-24
CR20160577A (es) 2017-01-06
KR102509950B1 (ko) 2023-03-14
UA121389C2 (uk) 2020-05-25
US11241448B2 (en) 2022-02-08
US20150335668A1 (en) 2015-11-26
SG10202003693RA (en) 2020-05-28
TW201613570A (en) 2016-04-16

Similar Documents

Publication Publication Date Title
JP6906564B2 (ja) 一次癌療法後に使用するためのホウ素含有プロテアソーム阻害剤
JP7626702B2 (ja) 癌の治療において使用するためのｃｓｆ１ｒ阻害剤
US20180353602A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
CA3101766A1 (en) Biomarkers for determining the effectiveness of immune checkpoint inhibitors
JP2024533423A (ja) 薬学的組成物およびその使用
US20250275955A1 (en) Use of tivozanib to treat subjects with refractory cancer
US20230130403A1 (en) Methods of treatment with s1p receptor modulators
KR20240124921A (ko) 약학적 조성물 및 이의 용도
KR20250149794A (ko) 유방암 치료 방법
KR20250085748A (ko) 약학적 조성물 및 이의 용도
AU2021424131A1 (en) Methods of treatment with s1p receptor modulators
Khubchandani Targeted therapies in B-cell non-Hodgkin lymphomas
Muneer et al. From: 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL, June 1-5, 2007

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191101